Sarcoma

Palbociclib and ganitumab combo shows limited efficacy for relapsed Ewing sarcoma

The combination therapy of palbociclib and ganitumab in Ewing sarcoma (EWS) did not demonstrate sufficient therapeutic activity to warrant further investigation, according to a study. However, a subset of patients experienced prolonged stable disease. The Phase 2 trial was an open-label, non-randomized study that enrolled patients aged ≥12 years who...